Neuropeptide Y Receptor Type 2 Pipeline Review H1 2017
ReportsWeb.com has announced the addition of the “Neuropeptide Y Receptor Type 2 Pipeline Review H1 2017” this report provides an overview of the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline landscape.
(EMAILWIRE.COM, July 06, 2017 ) Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene. It is expressed abundantly in the central nervous system. It is also seen in the spleen, liver and intestine. It regulates the release of neurotransmitters by functioning as an autoreceptor and heteroreceptor.
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase I and Preclinical stages are 1 and 4 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity, Epilepsy, Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.
The latest report Neuropeptide Y Receptor Type 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more information about this report at http://www.reportsweb.com/neuropeptide-y-receptor-type-2-pipeline-review-h1-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
- The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001858691/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Aevi Genomic Medicine Inc
Biohaven Pharmaceutical Holding Company Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001858691/discount
List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Gila Therapeutics Inc, H1 2017
Pipeline by Novo Nordisk A/S, H1 2017
Pipeline by XL-protein GmbH, H1 2017
Dormant Projects, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001858691/buy/3500
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase I and Preclinical stages are 1 and 4 respectively. Report covers products from therapy areas Metabolic Disorders and Central Nervous System which include indications Obesity, Epilepsy, Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.
The latest report Neuropeptide Y Receptor Type 2 - Pipeline Review, H1 2017, outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
For more information about this report at http://www.reportsweb.com/neuropeptide-y-receptor-type-2-pipeline-review-h1-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
- The report reviews Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001858691/sample
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Aevi Genomic Medicine Inc
Biohaven Pharmaceutical Holding Company Ltd
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001858691/discount
List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Gila Therapeutics Inc, H1 2017
Pipeline by Novo Nordisk A/S, H1 2017
Pipeline by XL-protein GmbH, H1 2017
Dormant Projects, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001858691/buy/3500
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results